行情

ASMB

ASMB

Assembly生物
NASDAQ

实时行情|Nasdaq Last Sale

15.51
+2.80
+21.98%
盘后: 15.04 -0.47 -3.03% 19:59 10/17 EDT
开盘
12.69
昨收
12.72
最高
18.62
最低
12.69
成交量
760.96万
成交额
--
52周最高
27.60
52周最低
8.13
市值
3.99亿
市盈率(TTM)
-4.2330
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ASMB 新闻

  • 对新兴市场货币交易员而言 美元不再是避险之选
  • 新浪财经综合.30分钟前
  • 国泰航空下调全年盈利预期
  • 新浪财经.57分钟前
  • 菲律宾拟对电子烟大幅加税
  • 新浪财经.1小时前
  • 沙特阿美:IPO时机将取决于市场条件和股东
  • 新浪财经.2小时前

更多

所属板块

制药
+0.54%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

ASMB 简况

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
展开

Webull提供Assembly Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。